RT @ATRIUMRx: New meta-analysis shows that aldosterone antagonists reduce mortality in elderly patients with HF, with a higher improvement…
RT @ATRIUMRx: New meta-analysis shows that aldosterone antagonists reduce mortality in elderly patients with HF, with a higher improvement…
Another reason to place more of an EMPHASIS on aldosterone antagonism...
RT @ATRIUMRx: New meta-analysis shows that aldosterone antagonists reduce mortality in elderly patients with HF, with a higher improvement…
RT @JBauersachsMD: Important Study! Also the elderly #heartfailure patients profit from MRA https://t.co/92YwDr7ncK
RT @ATRIUMRx: New meta-analysis shows that aldosterone antagonists reduce mortality in elderly patients with HF, with a higher improvement…
RT @ATRIUMRx: New meta-analysis shows that aldosterone antagonists reduce mortality in elderly patients with HF, with a higher improvement…
RT @CousiratLiendro: ¿Pueden los ancianos con IC obtener beneficios de los antagonistas de los receptores de mineralocorticoides? Metanáli…
RT @ATRIUMRx: New meta-analysis shows that aldosterone antagonists reduce mortality in elderly patients with HF, with a higher improvement…
New meta-analysis shows that aldosterone antagonists reduce mortality in elderly patients with HF, with a higher improvement in those with HFrEF. Compared to younger patients, elderly patients had worsening renal function but not hyperkalemia. #FOAMed http
RT @JACCJournals: Can older #heartfailure patients derive benefit from mineralocorticoid receptor antagonists? Meta-analysis of the RALES,…
RT @CousiratLiendro: ¿Pueden los ancianos con IC obtener beneficios de los antagonistas de los receptores de mineralocorticoides? Metanáli…
RT @CousiratLiendro: ¿Pueden los ancianos con IC obtener beneficios de los antagonistas de los receptores de mineralocorticoides? Metanáli…
RT @CousiratLiendro: ¿Pueden los ancianos con IC obtener beneficios de los antagonistas de los receptores de mineralocorticoides? Metanáli…
RT @CousiratLiendro: ¿Pueden los ancianos con IC obtener beneficios de los antagonistas de los receptores de mineralocorticoides? Metanáli…
RT @JACCJournals: Can older #heartfailure patients derive benefit from mineralocorticoid receptor antagonists? Meta-analysis of the RALES,…
RT @CousiratLiendro: ¿Pueden los ancianos con IC obtener beneficios de los antagonistas de los receptores de mineralocorticoides? Metanáli…
RT @JBauersachsMD: Important Study! Also the elderly #heartfailure patients profit from MRA https://t.co/92YwDr7ncK
Important Study! Also the elderly #heartfailure patients profit from MRA
So pleasing to see this MA for use of #MRAs in elderly #HeartFailure pts by the leaders in the MR RCTs in @JACCJournals Older defined as ≥75 yrs
RT @JACCJournals: Can older #heartfailure patients derive benefit from mineralocorticoid receptor antagonists? Meta-analysis of the RALES,…
RT @JACCJournals: Can older #heartfailure patients derive benefit from mineralocorticoid receptor antagonists? Meta-analysis of the RALES,…
RT @CousiratLiendro: ¿Pueden los ancianos con IC obtener beneficios de los antagonistas de los receptores de mineralocorticoides? Metanáli…
RT @JACCJournals: Can older #heartfailure patients derive benefit from mineralocorticoid receptor antagonists? Meta-analysis of the RALES,…
RT @JACCJournals: Can older #heartfailure patients derive benefit from mineralocorticoid receptor antagonists? Meta-analysis of the RALES,…
RT @CousiratLiendro: ¿Pueden los ancianos con IC obtener beneficios de los antagonistas de los receptores de mineralocorticoides? Metanáli…
RT @CousiratLiendro: ¿Pueden los ancianos con IC obtener beneficios de los antagonistas de los receptores de mineralocorticoides? Metanáli…
RT @JACCJournals: Can older #heartfailure patients derive benefit from mineralocorticoid receptor antagonists? Meta-analysis of the RALES,…
RT @CousiratLiendro: ¿Pueden los ancianos con IC obtener beneficios de los antagonistas de los receptores de mineralocorticoides? Metanáli…
RT @CousiratLiendro: ¿Pueden los ancianos con IC obtener beneficios de los antagonistas de los receptores de mineralocorticoides? Metanáli…
RT @CousiratLiendro: ¿Pueden los ancianos con IC obtener beneficios de los antagonistas de los receptores de mineralocorticoides? Metanáli…
RT @CousiratLiendro: ¿Pueden los ancianos con IC obtener beneficios de los antagonistas de los receptores de mineralocorticoides? Metanáli…
RT @JACCJournals: Can older #heartfailure patients derive benefit from mineralocorticoid receptor antagonists? Meta-analysis of the RALES,…
RT @CousiratLiendro: ¿Pueden los ancianos con IC obtener beneficios de los antagonistas de los receptores de mineralocorticoides? Metanáli…
¿Pueden los ancianos con IC obtener beneficios de los antagonistas de los receptores de mineralocorticoides? Metanálisis de RALES, EMPHASIS-HF y TOPCAT 💔 @JACCJournals @SIAC_cardio @gonzaeperez @j_alvarezgarcia https://t.co/NUpGc9t2zI
RT @JACCJournals: Can older #heartfailure patients derive benefit from mineralocorticoid receptor antagonists? Meta-analysis of the RALES,…
RT @JACCJournals: Can older #heartfailure patients derive benefit from mineralocorticoid receptor antagonists? Meta-analysis of the RALES,…
RT @JACCJournals: Can older #heartfailure patients derive benefit from mineralocorticoid receptor antagonists? Meta-analysis of the RALES,…
Can older #heartfailure patients derive benefit from mineralocorticoid receptor antagonists? Meta-analysis of the RALES, EMPHASIS-HF & TOPCAT trials report consistent reduction in CV events in this high-risk subset. https://t.co/bzC1iWD7Oi #JACCHF @co
MRAs in Elderly HF Patients https://t.co/ZcJ2xV9Azg
@asanakpan
RT @DrWillWatson: https://t.co/4VjQyheL6O MRAs are also perfectly fine in older people with heart failure #heartfailure https://t.co/rwswL9…
https://t.co/4VjQyheL6O MRAs are also perfectly fine in older people with heart failure #heartfailure https://t.co/rwswL9HOUG
RT @vic_pallares: MRAs in Elderly HF Patients➡️Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT. 📣MRAs⤵️morbidity&mo…
RT @vic_pallares: MRAs in Elderly HF Patients➡️Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT. 📣MRAs⤵️morbidity&mo…
RT @SophiaAirhart: MRAs in Elderly HF Patients | JACC: Heart Failure @JACCJournals 👇MRAs safe in >75 yo with monitoring and reduced morb…
MRAs in Elderly HF Patients | JACC: Heart Failure @JACCJournals 👇MRAs safe in >75 yo with monitoring and reduced morbidity and mortality in HFrEF and HFpEF https://t.co/fHZN1zIgur
Este efecto beneficioso es más marcado en pacientes con insuficiencia cardíaca con fracción de eyección reducida. Definitivamente se justifica la implementación de medidas que aumenten el tratamiento con ARM en esta población. https://t.co/0nSWtqLAxd
RT @vic_pallares: MRAs in Elderly HF Patients➡️Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT. 📣MRAs⤵️morbidity&mo…
RT @vic_pallares: MRAs in Elderly HF Patients➡️Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT. 📣MRAs⤵️morbidity&mo…
RT @vic_pallares: MRAs in Elderly HF Patients➡️Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT. 📣MRAs⤵️morbidity&mo…
RT @vic_pallares: MRAs in Elderly HF Patients➡️Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT. 📣MRAs⤵️morbidity&mo…
RT @vic_pallares: MRAs in Elderly HF Patients➡️Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT. 📣MRAs⤵️morbidity&mo…
RT @vic_pallares: MRAs in Elderly HF Patients➡️Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT. 📣MRAs⤵️morbidity&mo…
RT @vic_pallares: MRAs in Elderly HF Patients➡️Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT. 📣MRAs⤵️morbidity&mo…
MRAs in Elderly HF Patients➡️Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT. 📣MRAs⤵️morbidity&mortality in elderly patients w/ HF, a beneficial effect that is more marked in patients w/ HFrEF but homogenous across HFrEF & H
Individual patient data meta-analysis of 3 MRA trials (EMPHASIS, TOPCAT [Americas], and RALES) showing similar benefits and reasonable safety on older adults across HFrEF and HFpEF populations. https://t.co/uSFI0a5KjJ
RT @FormigaFrancesc: MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of ... https://t.co/JH92VoRUJc
RT @novitskiynic: 📌MRAs in Elderly HF Patients: IPD Meta-Analysis of RALES, EMPAHSIS-HF and TOPCAT. 💊MRAs⤵️morbidity and mortality in 👨🏼🦳…
RT @RosselloXavier: MRAs in Elderly HF Patients Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT JP Ferreira, X Ros…
RT @RosselloXavier: MRAs in Elderly HF Patients Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT JP Ferreira, X Ros…
RT @FormigaFrancesc: MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of ... https://t.co/JH92VoRUJc
RT @FormigaFrancesc: MRAs reduce morbidity and mortality in elderly patients (age 75 or more) with HF, with a homogenous treatment effect b…
RT @novitskiynic: 📌MRAs in Elderly HF Patients: IPD Meta-Analysis of RALES, EMPAHSIS-HF and TOPCAT. 💊MRAs⤵️morbidity and mortality in 👨🏼🦳…
RT @RosselloXavier: MRAs in Elderly HF Patients Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT JP Ferreira, X Ros…
Nice
RT @novitskiynic: 📌MRAs in Elderly HF Patients: IPD Meta-Analysis of RALES, EMPAHSIS-HF and TOPCAT. 💊MRAs⤵️morbidity and mortality in 👨🏼🦳…
RT @novitskiynic: 📌MRAs in Elderly HF Patients: IPD Meta-Analysis of RALES, EMPAHSIS-HF and TOPCAT. 💊MRAs⤵️morbidity and mortality in 👨🏼🦳…
RT @RosselloXavier: MRAs in Elderly HF Patients Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT JP Ferreira, X Ros…
RT @novitskiynic: 📌MRAs in Elderly HF Patients: IPD Meta-Analysis of RALES, EMPAHSIS-HF and TOPCAT. 💊MRAs⤵️morbidity and mortality in 👨🏼🦳…
RT @novitskiynic: 📌MRAs in Elderly HF Patients: IPD Meta-Analysis of RALES, EMPAHSIS-HF and TOPCAT. 💊MRAs⤵️morbidity and mortality in 👨🏼🦳…
RT @davidcalle1390: De obligada lectura! Historia reciente y presente. Orgulloso del Dr @RosselloXavier , trabajador incansable, crack, un…
RT @FormigaFrancesc: MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of ... https://t.co/JH92VoRUJc
ANTAGONIZE to ENERGIZE! MR antagonists reduced morbidity and mortality in #elderly patients with #HeartFailure, a beneficial effect that is more marked in patients with HFrEF but homogenous across HFrEF and HFpEF #SuccessInFailure
RT @RosselloXavier: MRAs in Elderly HF Patients Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT JP Ferreira, X Ros…
RT @RosselloXavier: MRAs in Elderly HF Patients Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT JP Ferreira, X Ros…
De obligada lectura! Historia reciente y presente. Orgulloso del Dr @RosselloXavier , trabajador incansable, crack, un ejemplo donde mirarnos! @CNIC_CARDIO https://t.co/728TwYF8sR
RT @RosselloXavier: MRAs in Elderly HF Patients Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT JP Ferreira, X Ros…
RT @novitskiynic: 📌MRAs in Elderly HF Patients: IPD Meta-Analysis of RALES, EMPAHSIS-HF and TOPCAT. 💊MRAs⤵️morbidity and mortality in 👨🏼🦳…
RT @novitskiynic: 📌MRAs in Elderly HF Patients: IPD Meta-Analysis of RALES, EMPAHSIS-HF and TOPCAT. 💊MRAs⤵️morbidity and mortality in 👨🏼🦳…
MRAs in Elderly HF Patients Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT JP Ferreira, X Rossello, R Eschalier, JJV McMurray, SP Pocock, N Girerd, P Rossignol, B Pitt, F Zannad JACC: heart failure @secardiologia @HaroBosch htt
RT @FormigaFrancesc: MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of ... https://t.co/JH92VoRUJc
RT @novitskiynic: 📌MRAs in Elderly HF Patients: IPD Meta-Analysis of RALES, EMPAHSIS-HF and TOPCAT. 💊MRAs⤵️morbidity and mortality in 👨🏼🦳…
RT @novitskiynic: 📌MRAs in Elderly HF Patients: IPD Meta-Analysis of RALES, EMPAHSIS-HF and TOPCAT. 💊MRAs⤵️morbidity and mortality in 👨🏼🦳…
RT @novitskiynic: 📌MRAs in Elderly HF Patients: IPD Meta-Analysis of RALES, EMPAHSIS-HF and TOPCAT. 💊MRAs⤵️morbidity and mortality in 👨🏼🦳…
RT @novitskiynic: 📌MRAs in Elderly HF Patients: IPD Meta-Analysis of RALES, EMPAHSIS-HF and TOPCAT. 💊MRAs⤵️morbidity and mortality in 👨🏼🦳…
RT @novitskiynic: 📌MRAs in Elderly HF Patients: IPD Meta-Analysis of RALES, EMPAHSIS-HF and TOPCAT. 💊MRAs⤵️morbidity and mortality in 👨🏼🦳…
RT @novitskiynic: 📌MRAs in Elderly HF Patients: IPD Meta-Analysis of RALES, EMPAHSIS-HF and TOPCAT. 💊MRAs⤵️morbidity and mortality in 👨🏼🦳…
📌MRAs in Elderly HF Patients: IPD Meta-Analysis of RALES, EMPAHSIS-HF and TOPCAT. 💊MRAs⤵️morbidity and mortality in 👨🏼🦳👵🏻>75 w #HF, especially in HFrEF, but homogenous across HFrEF and HFpEF ☝️Worsening renal function and hyper-K more often on MRAs 📎
RT @FormigaFrancesc: MRAs reduce morbidity and mortality in elderly patients (age 75 or more) with HF, with a homogenous treatment effect b…
RT @FormigaFrancesc: MRAs reduce morbidity and mortality in elderly patients (age 75 or more) with HF, with a homogenous treatment effect b…
MRAs reduce morbidity and mortality in elderly patients (age 75 or more) with HF, with a homogenous treatment effect between HFrEF and HFpEF (and between younger and older patients) @IcyfaSemi @secardiologia @seggeriatria
MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of ... https://t.co/JH92VoRUJc